EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Comparative Efficacy of Three Oral Itraconazole Formulations in Superficial Dermatophytosis

Harsh Tyagi iD, Shitij Goel iD, Aneesha Puri iD, Isha Singla iD, Anmol Rathore iD

Mycoses · 2025-06 · 68 (6)

DOI: 10.1111/myc.70080 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Mycoses, online erschienen am 19.06.2025. Verfasst von Harsh Tyagi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, School of Medical Sciences and Research, Sharda Hospital, Greater Noida, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Antifungal Agents, Itraconazole, Tinea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dermatophytosis is a chronic public health issue in India, often requiring systemic antifungals. Itraconazole (ITZ) is commonly used, but conventional forms show variable absorption. Super‐bioavailable itraconazole (SUBA‐ITZ) offers improved pharmacokinetics, though clinical comparisons are limited.

Objective

To compare the efficacy, safety, relapse, and recurrence rates of three oral ITZ formulations—Conventional ITZ 100 mg (C‐ITZ), SUBA‐ITZ 65 mg, and SUBA‐ITZ 50 mg—in superficial dermatophytosis.

Methods

In this open‐label, randomised study at a tertiary hospital, 150 patients with confirmed tinea corporis, cruris, or faciei were equally assigned to: Group A: C‐ITZ 100 mg BID Group B: SUBA‐ITZ 65 mg BID Group C: SUBA‐ITZ 50 mg BID Treatment lasted 6 weeks without topical antifungals. Assessments were done at 3 and 6 weeks; relapse and recurrence were monitored telephonically at 3 and 6 months.

Results

All groups showed similar clinical response at 6 weeks (BSA, PGA, KOH negativity), with no significant differences. At 3 months, Group C had significantly lower relapse and recurrence (10.2%) than Group B (31.1%, 28.9%) and Group A (23.9%, 26.1%) ( p < 0.05). By 6 months, differences were not significant.

Conclusion

All three itraconazole formulations demonstrated comparable short‐term efficacy in treating superficial dermatophytosis. These findings underscore the need for larger, long‐term randomised controlled trials to optimise itraconazole dosing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsItraconazoleTineaAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralIndiaRecurrenceTreatment Outcome

Stichwörter der Autor:innen

dermatophytosisitraconazolesuper‐bioavailable itraconazole

Substanzen

Antifungal AgentsItraconazole

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Leprology, School of Medical Sciences and Research, Sharda Hospital, Greater Noida, Uttar Pradesh, India.

ORCID-Profile: Harsh Tyagi, Shitij Goel, Aneesha Puri, Isha Singla, Anmol Rathore

Zitieren

APA

Tyagi, H., Goel, S., Puri, A., Singla, I., & Rathore, A. (2025). Comparative Efficacy of Three Oral Itraconazole Formulations in Superficial Dermatophytosis. Mycoses, 68(6). https://doi.org/10.1111/myc.70080

Vancouver

Tyagi H, Goel S, Puri A, Singla I, Rathore A. Comparative Efficacy of Three Oral Itraconazole Formulations in Superficial Dermatophytosis. Mycoses. 2025;68(6). doi:10.1111/myc.70080

BibTeX
@article{Tyagi2025,
  author = {Tyagi, Harsh and Goel, Shitij and Puri, Aneesha and Singla, Isha and Rathore, Anmol},
  title = {Comparative Efficacy of Three Oral Itraconazole Formulations in Superficial Dermatophytosis},
  journal = {Mycoses},
  year = {2025},
  volume = {68},
  number = {6},
  doi = {10.1111/myc.70080}
}
Kostenlos starten →